Compare CarMax, Inc (KMX) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Novavax Inc — how do they compare? CarMax, Inc trades at $52.72 (market cap $7.64B), while Novavax Inc trades at $12.74 (market cap $1.82B). The key difference: CarMax, Inc is far larger — about 4.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Novavax Inc for 59 Days on average.
| KMX | NVAX | |
|---|---|---|
Market Cap | $7.64B | $1.82B |
Volume | 3,610,116 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $12.56 |
52-Week Low | $30.88 | $6.22 |
Typical Hold Time | 49 Days | 59 Days |
Enterprise Value | $25.34B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $52.61, down 1.26% amid bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 25.37 and net margin of 1.06%, while revenue trends downward from $31.9B in 2022 to $26.4B in 2025. Recent Q2 2026 earnings of $1.16 per share beat expectations by 58%, driven by 19.5% revenue growth and improved unit sales under the 'Shift into GEAR' strategy.
The outlook remains cautious with analyst consensus at Hold (62%) and $58.89 price target suggesting 12% upside. Key risks include declining profit margins, high debt load ($18.14B long-term), and competitive pressures. Positive catalysts include continued execution of turnaround strategy and November 3 strategic update.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
